Mergers News
Thursday, January 26, 2017
Actelion top-40 investor calls J&J buyout "very attractive"
ZURICH, Jan 26 (Reuters) - Johnson & Johnson's $30
billion offer to buy Swiss biotech Actelion including a
plan to spin out a separate research company is "very
attractive", one of Actelion's 40...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment